GlaxoSmithKline has begun a phase III clinical study that will compare comparing its drug Tykerb with Herceptin in the treatment of early breast cancer. The trial will measure which cancer cells disappear in the breast following treatment with Tykerb and/or Herceptin before surgery in women with early-stage breast cancer whose tumours overexpress the HER2 protein.
A resident of Honolulu, Hawaii, Wayne Parsons is an Injury Attorney that has dedicate his life to improving the delivery of justice to the people of his community and throughout the United States. He is driven to make sure that the wrongful, careless or negligent behavior that caused his clients' injury or loss does not happen to others.
Comments for this article are closed.